Mutation SF3B1
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-SF3B1 |
|---|---|
| Type | Biomarqueur |
| Alias | SF3B1 K700EМутація SF3B1 |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"functional_impact": "Aberrant 3' splice-site recognition → cryptic exon inclusion → nonsense-mediated decay of target transcripts (e.g. ABCB7 in MDS-RS)", "gene": "SF3B1", "gene_hugo_id": "HGNC:10768", "hotspots": ["K700E (~50% of SF3B1-mutant cases — most common)", "K666N / K666E / K666T", "H662 / R625 / E622"], "variant_type": "missense (HEAT-domain hotspots)"} |
| Mesure | MéthodePanneau ADN-NGS (panneau myéloïde, panneau lymphoïde ou grand panneau de tumeurs solides) UnitésCatégorie; FAV signalée Exigence de sensibilitéNorme NG |
| Biomarqueurs connexes | BIO-CLL-HIGH-RISK-GENETICS |
Notes
MDS: ~20% overall, ~80% of MDS with ring sideroblasts (MDS-LR-RS in WHO-2022 / ICC-2022). SF3B1-mutant MDS-LR-RS has a distinct biology — favorable in IPSS-M, transfusion-dependent anemia phenotype, responds to luspatercept (COMMAND, MEDALIST). Also luspatercept ESAs first-line for low-risk MDS irrespective of RS in some regions per ESMO 2024 update. CLL: ~10–20%, adverse prognostic marker. Uveal melanoma: ~20%, intermediate prognosis (vs BAP1 worst). H3B-8800 / E7107 splicing modulators in development but no approved agents target SF3B1 directly.
Utilisé par
No reverse references found in the YAML corpus.